Newpong drew attention from industry professionals by showcasing its ultrasound lipolysis device, LSSA, at the 2025 ISAPS World Congress.

Newpong recently announced that it participated in the 2025 ISAPS World Congress, held in Singapore, where it showcased its ultrasound fat-dissolving medical device, LSSA (Liposound Subcision System Advance).

The ISAPS World Congress is an international event uniting major plastic surgery societies around the world—such as KSAPS, VSAPS, and ASAPS. Held annually, the congress serves as a platform to share the latest surgical techniques and medical technologies based on trends and statistics in plastic surgery. This year’s congress saw the participation of key players in the aesthetic medical device industry, with particularly intense competition in the fields of liposuction and tissue-targeting technologies.

At the event, Newpong’s LSSA attracted significant attention from attending medical professionals for its ability to perform precise fat dissolution and tissue subcision using an ultra-fine Ø0.9mm probe. In particular, its non-invasive approach offered enhanced safety and tissue preservation, while the intuitive power output system—designed to improve practitioner convenience—was highlighted as a key differentiating strength.

LSSA is a fat-dissolving medical device that enables precise fat emulsification and tissue subcision using an ultra-fine Ø0.9mm probe.

During the academic sessions, real surgical cases using LSSA were presented, highlighting both the device’s effectiveness and clinical utility. Among participating medical professionals, discussions followed regarding its clinical applicability, as well as its potential for future presentations and academic publications. The device was also positively evaluated for its potential to be expanded into various aesthetic and reconstructive procedures.

Through this exhibition, Newpong also began discussions with various international partners regarding equipment testing and distribution, and initial supply talks are already underway in some regions of Europe and Asia.

A Newpong representative stated, “Through our participation in ISAPS, we were able to validate the technological strength, product safety, and global competitiveness of our devices,” adding, “We plan to actively expand into overseas markets through clinical evidence-based academic presentations and a physician-centered marketing strategy.”

Meanwhile, LSSA has completed most of the preliminary domestic testing required for FDA registration in the United States. Newpong is also in the process of establishing strategic partnerships to obtain CE certification and expand into markets in the Middle East and Southeast Asia.

►View Full Article